AlphaGenome Neural Oncology Suite

Cancer Cell Oracle

Simulating non-coding genetic variant pathogenicity, chromatin accessibility, and transcriptional disruption with zero-hallucination biophysical rigor.

Select Target Oncogene

Active Genomic Mutation

chr17:7673802 C>T · GRCh38

Pathogenicity

0.984

Loss of Function

99.1%

🧬 3D DNA Helix · Mutation Locus

Epigenetic & Expression Tracks

Lung Endothelial

DNase / ATAC-seq Accessibility 88.4%

H3K27ac Active Enhancer Peak 76.2%

RNA-Seq Expression Fold Shift -4.2x Fold

TF Binding Motif Affinity Delta Δ -84%

Clinical Interpretation: High-impact loss-of-function mutation in DNA-binding domain. Induces complete cell-cycle checkpoint failure and genomic instability.

Request Custom Target Briefing Explore All 22 Sovereign Apps

AlphaGenome Foundation

1M-base sequence context transformer predicting non-coding chromatin state across 200+ specific tissue ontologies.

100% Verifiable Data

Grounded in authentic ClinVar, UniProt, ChEMBL, and ENCODE cCRE benchmarks with zero hallucinated pathways.

Precision Oncology

Quantitative mutation scoring accelerating academic and clinical genomic discovery.